human |
hsa_circ_TADA2A |
hsa_circ_0043278 |
- |
lung non-small cell carcinoma |
TADA2A |
hsa-miR-520f |
Q
| |
More |
human |
hsa_circ_TADA2A |
- |
- |
osteosarcoma |
TADA2A |
hsa-miR-203a-3p |
Q
S
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0006220 |
- |
breast cancer |
TADA2A |
- |
M
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0043278 |
- |
breast cancer |
TADA2A |
- |
M
| |
More |
human |
hsa_circ_TADA2A |
- |
- |
colorectal cancer |
TADA2A |
hsa-miR-374a-3p |
Q
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0106714 |
- |
colorectal cancer |
TADA2A |
hsa-miR-942-5p |
Q
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0043278 |
- |
brain glioblastoma multiforme |
TADA2A |
hsa-miR-638 |
Q
| |
More |
human |
hsa_circ_TADA2A |
- |
circTADA2A |
osteosarcoma |
TADA2A |
hsa-miR-129-5p |
Q
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0043278 |
- |
breast cancer |
TADA2A |
- |
Q
S
| |
More |
human |
hsa_circ_TADA2A |
- |
circTADA2A |
lung non-small cell carcinoma |
TADA2A |
hsa-miR-638 |
Q
| |
More |
human |
hsa_circ_TADA2A |
- |
circTADA2A |
colorectal cancer |
TADA2A |
hsa-miR-1229 |
Q
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0006220 |
- |
triple-receptor negative breast cancer |
TADA2A |
hsa-miR-197-5p |
Q
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0043280 |
- |
cervical cancer |
TADA2A |
hsa-miR-203a-3p |
Q
M
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0043278 |
- |
breast cancer |
TADA2A |
hsa-miR-455-3p |
Q
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0006220 |
Circ_0006220 |
lung non-small cell carcinoma |
TADA2A |
hsa-miR-203-3p |
Q
| |
More |
human |
hsa_circ_TADA2A |
- |
circTADA2A |
lung non-small cell carcinoma |
TADA2A |
hsa-miR-450b-3p |
Q
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0006220 |
Exosomal circular RNA |
pancreatic cancer |
TADA2A |
- |
Q
M
| |
More |
human |
hsa_circ_TADA2A |
- |
CircTADA2A |
lung non-small cell carcinoma |
TADA2A |
hsa-miR-214-3p |
Q
| |
More |
human |
hsa_circ_TADA2A |
hsa_circ_0006220 |
Circ_0006220 |
lung non-small cell carcinoma |
TADA2A |
hsa-miR-342-3p |
Q
| |
More |